LINC00664: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC00664

NCBI ID: G400680

LINC00664

Other Name(s): long intergenic non-protein coding RNA 664 | Long intergenic non-protein coding RNA 664

LINC00664: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC00664 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in various tissues and cells in the human body. LINC00664 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

The Discovery and Characterization of LINC00664

LINC00664 was first identified using RNA sequencing (RNA-seq) technology. RNA-seq is a high-throughput sequencing technology that allows researchers to identify and quantify gene expression in a sample. The LINC00664 gene was identified by RNA-seq analysis and has been shown to have a strong expression in various tissues and cells.

To further investigate the function of LINC00664, researchers used a variety of techniques to study its expression and function in live cells. One approach was to use RNA interference (RNAi) to knockdown the expression of LINC00664 in cell culture and to assess the effects on cellular processes. RNAi screening revealed that LINC00664 was involved in the regulation of cell adhesion, migration, and survival.

Another approach was to use live cell imaging to visualize the localization and distribution of LINC00664 in various tissues and cells. Using this technique, researchers found that LINC00664 was expressed in various tissues, including the brain, heart, and pancreas, and was localized to the cytoplasm.

The Potential therapeutic Potential of LINC00664

The therapeutic potential of LINC00664 is due to its involvement in various cellular processes that are important for human health. LINC00664 has been shown to play a role in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. In addition, LINC00664 has been shown to be involved in the regulation of cell migration, which is important for the development and maintenance of tissues and organs.

In addition to its role in cell adhesion and migration, LINC00664 has also been shown to play a role in the regulation of cell survival. LINC00664 has been shown to play a negative role in the regulation of cell survival by suppressing the expression of genes that are involved in cell apoptosis.

The therapeutic potential implications of LINC00664 are significant. Because it plays a role in the regulation of cell adhesion, migration and survival, it may be a useful target for new therapies for various diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases.

Conclusion

LINC00664 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its functions in the regulation of cell adhesion, migration and survival make it a promising target for new therapies. Further research is needed to fully understand the role of LINC00664 in various cellular processes and to develop effective therapies based on its properties.

Protein Name: Long Intergenic Non-protein Coding RNA 664

The "LINC00664 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00664 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets